Clinical trial · Interventional
A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer
Stand Up to Cancer Consortium: Phase II Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated With Metastatic Pancreatic Cancer
NCT01196247CI-TRIAL-00007448completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is selecting second line therapy for patients with pancreatic cancer using molecular profiling will improve 1 year survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Previously Treated Metastatic Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Determine the percent of patients who are alive at one year
- timeFrame
- One year
- description
- Goal is to improve the one year survival (from start of first-line therapy for metastatic disease) to 60%
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * metastatic adenocarcinoma of the pancreas * male or non-pregnant female * 18 years of age or greater * one prior therapy for the treatment of metastatic disease * must start continuation therapy within 9 months of starting first line treatment * have adequate organ and bone marrow function * must have a Karnofsky performance status greater than or equal to 70 * one or more metastatic tumors measurable by CT scan and accessible for biopsy Exclusion Criteria: * operable or locally advanced pancreatic cancer * metastatic tumor that is not amendable to biopsy * known brain mets unless previously treated and well controlled * active, uncontrolled bacterial, viral or fungal infections * known infection with HIV, hepatitis B or hepatitis C * pregnant or breast-feeding patients
References
Publications (0)
Data not yet available
No reference posted for this study.